Skip to main content

Table 4 Multivariable analysis on baseline plasma NfL levels with cognitive and motor outcomes in PD patients over time

From: Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease

Outcomes

MDS-UPDRS Part III (Motor)a

MMSE

β (95% CI)b

p value

β (95% CI)

p value

NfL (PIGD)

9.73 (3.65, 15.81)

0.002

− 2.09 (−3.90, − 0.28)

0.024

NfL (TD)

−3.90 (− 9.36, 1.57)

0.161

0.50 (− 1.14, 2.13)

0.549

NfL x Motor Subtype

13.6 (6.16, 21.1)

< 0.001

−2.59 (− 4.81, − 0.36)

0.023

Age

0.10 (− 0.12, 0.32)

0.385

−0.08 (− 0.14, − 0.01)

0.025

Gender

−2.75 (− 5.84, 0.35)

0.081

−0.09 (− 1.01, 0.83)

0.839

Disease duration

−0.75 (− 2.43, 0.93)

0.379

0.17 (− 0.34, 0.69)

0.506

  1. Abbreviations: PD Parkinson’s Disease; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MMSE Mini Mental State Examination; CI Confidence Interval; NfL Neurofilament light chain protein
  2. a MDS-UPDRS Part III (Motor) and MMSE scores of PD patients over 2 years are the outcome variables
  3. b Beta coefficient (and 95% CI) of Ln-NfL level; Linear mixed models adjusted for age, sex, disease duration and NfL x motor subtype interaction
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326